Simple Summary Bladder cancer is the ninth most common cancer worldwide. Immune
checkpoint inhibitors, a novel class of immunotherapy drugs that restore natural antitumoral …

Metabolomic analysis has proven to be a useful tool in biomarker discovery and the
molecular classification of cancers. In order to find new biomarkers, and to better understand …

For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the
form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line …

Introduction Several programmed death ligand-1 (PD1/L1) immune checkpoint inhibitors
(ICIs) are approved in urothelial carcinoma (UC). Patients and Methods To address the need …

Background Combinations of immune checkpoint inhibitors (ICI) with platinum-based
chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with …

Simple Summary Bladder cancer is evidently a challenge as far as its prognosis and
treatment are concerned. The investigation of potential biomarkers and therapeutic targets is …

Simple Summary In muscle-invasive bladder cancer, platinum-based neoadjuvant
chemotherapy is a well-established concept, since it contributes to pathological …

Background Oxidative stress plays an important role in the occurrence and development of
malignancy. However, the relationship between oxidative stress and upper urinary tract …

Bladder cancer (BLCA) is one of the most common types of malignant tumors of the
urogenital system in adults. Globally, the incidence of BLCA is more than 500,000 new …

Background Leucinerich repeatcontaining protein 59 (LRRC59) is an endoplasmic
reticulum membrane protein involved in various cancers, but its role in bladder cancer (BC) …